Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 65 years old at the time of joining the trial
- People who have a blood cancer or other cancer of the blood system
- People whose doctors have determined they are suitable to receive a stem cell transplant from a donor, and are well enough to receive the specific treatment plan used in this trial
- People for whom no fully matched related family donor or fully matched unrelated donor has been found
- People for whom two suitable umbilical cord blood (UCB) units are available that meet specific tissue-matching requirements set by the trial
- People for whom at least one of those cord blood units meets a minimum cell count requirement set by the trial (confirm with trial site for exact details)
- People who do not have certain antibodies in their blood that could attack the donor cord blood cells (confirm with trial site)
- People who are enrolled in a social security system (this appears to be a French/European healthcare requirement — confirm with trial site)
- People who have given written agreement to take part in the trial
Who may not be able to join:
- People who have any standard medical reason that would prevent them from having a donor stem cell transplant
- People whose heart is not pumping blood efficiently enough (heart pump function below a certain level)
- People whose liver or kidney function test results fall outside acceptable ranges set by the trial
- People who are unable to understand the trial information or provide their own consent to participate
- People who currently have HIV-I, HIV-II, or HTLV-I infections
- People who are pregnant or breastfeeding
- People whose blood cancer is currently getting worse or spreading
- People who have taken part in another clinical trial involving drugs that could affect immune system recovery within the month before joining this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Olivier HERMINE, PhD & MD, Assistance Publique - Hôpitaux de Paris
Phone: +33 144495282
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cumulative incidence of grade III-IV graft-versus-host disease (GvHD); CD4 + T cells analysis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.